Viking Therapeutics (VKTX) Reports In-Line Q2 EPS

Viking Therapeutics (NASDAQ: VKTX) reported Q2 EPS of ($0.20), in-line with the analyst estimate of ($0.20).

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• Morgan Stanley Starts Target Hospitality (TH) at Overweight